Health Canada Terms and Conditions for Drugs: How Agile Licensing Replaces NOC/c by 2027

A practical guide for sponsors, market authorization holders, and regulatory affairs leaders preparing for the new terms and conditions framework taking effect April 1, 2027.

Health Canada is changing how it licenses drugs. On December 12, 2025, the department published two draft guidance documents that explain when and how it will attach terms and conditions (T&Cs) to a drug authorization. These documents put detail behind the Agile Licensing amendments to the Food and Drug Regulations, which come into force on April 1, 2027. For sponsors, this is one of the most significant shifts in Canadian drug regulation since Vanessa's Law, and it deserves attention now while the framework is still in consultation.

This article explains what the new terms and conditions authority means, how the long-standing Notice of Compliance with Conditions (NOC/c) pathway is being replaced, and what lifecycle obligations market authorization holders will carry. It is written for regulatory and quality leaders who need to translate the policy into concrete planning.

Executive Summary

Terms and conditions are enforceable obligations that Health Canada can place on a drug identification number (DIN) at any point in a product's lifecycle. The authority flows from new section C.01.014.21 of the Food and Drug Regulations and applies to almost any drug with a DIN, including prescription and non-prescription pharmaceuticals, biologics, and radiopharmaceuticals.

The headline change for innovators is the replacement of the NOC/c policy. Promising new drugs for serious conditions that would once have been approved under NOC/c will instead be authorized with terms and conditions under section C.08.003.2, supported by a new promising evidence of clinical efficacy pathway. T&Cs are enforceable under section 21.7 of the Food and Drugs Act, and a market authorization holder who fails to meet them may face criminal liability and regulatory actions up to and including cancellation of the DIN.

The consultation on both draft guidance documents closed on February 10, 2026. The regulatory amendments take effect on April 1, 2027, so sponsors have a defined window to prepare submission strategies, confirmatory study plans, and lifecycle compliance systems.

What Are Terms and Conditions on a Drug Authorization?

Terms and conditions are binding obligations Health Canada imposes on a drug's DIN to manage risks or resolve significant uncertainties about its benefits, risks, or quality. They are not a way to fix a deficient submission. They are a tool to keep a drug's benefit-risk profile favourable over its entire commercial life.

Under section C.01.014.21 of the Food and Drug Regulations, the Minister may impose or amend T&Cs at any time after considering whether there are significant uncertainties about the drug's benefits or risks, whether existing requirements are sufficient, whether the proposed T&Cs are technically feasible, and whether less burdensome options exist. Health Canada must notify the manufacturer in writing of any T&Cs imposed or amended.

In plain terms, a market authorization holder (MAH) can be required to run additional studies, verify identified impurities, strengthen a risk management or monitoring program, or file summary safety reports more often than the annual minimum the regulations already require. The obligation is documented in a formal terms and conditions letter that names the affected DINs, the conditions to fulfill, the information to submit, and the deadline.

This authority builds on the lifecycle approach to drug regulation introduced by the Protecting Canadians from Unsafe Drugs Act, known as Vanessa's Law, which received Royal Assent in 2014. Vanessa's Law gave the Governor in Council the power to make regulations supporting post-market oversight. The Agile Licensing amendments are the next step in that lifecycle model.

Why the Change Matters for Sponsors

The new framework matters because it expands Health Canada's reach across the full product lifecycle and raises the compliance stakes for every market authorization holder. A T&C is no longer a niche tool tied to one conditional approval pathway. It is a general authority that can touch any DIN, from a newly approved biologic to a generic that has been on the market for years.

Clinical trials cannot answer every question about how a drug performs in the real world. Trial inclusion and exclusion criteria, limited duration, and small patient numbers all create gaps. Health Canada has been clear that it will use T&Cs to close those gaps: to monitor long-term safety, to study effects in populations not represented in trials, to track interactions with other drugs, and to respond to new signals from foreign regulators or published evidence. For sponsors, that means a market authorization is increasingly a starting point for ongoing obligations rather than a finish line.

The practical consequence is that regulatory, clinical, and quality teams need to plan for post-market commitments at the time of submission, not after approval. Companies that treat T&Cs as an afterthought risk missed deadlines, enforcement action, and reputational harm. Our regulatory affairs consulting team works with sponsors to build that planning into the submission strategy from the outset.

How Terms and Conditions Replace the NOC/c Pathway

The Notice of Compliance with Conditions policy is being replaced by terms and conditions imposed under the new promising evidence pathway. For two decades, NOC/c allowed Health Canada to approve promising drugs for serious or life-threatening conditions on the basis of promising evidence, on the condition that the sponsor confirm clinical benefit through later studies. The Agile Licensing framework moves that concept into the regulations themselves.

Under the new model, a new drug submission (NDS) or supplement to a new drug submission (SNDS) for a serious or severely debilitating condition can be authorized based on promising evidence of clinical efficacy. Where significant uncertainties about effectiveness remain, Health Canada applies section C.08.003.2 of the Food and Drug Regulations to impose T&Cs that require confirmatory studies. The confirmatory results are later filed as a supplement to a new drug submission, confirmatory, known as an SNDS-C.

The promising evidence pathway also introduces a new mechanism to speed access. Sponsors of human drugs can request Advance Consideration of Promising Evidence (ACPE) status, which leads to reduced screening and review targets when the submission meets defined criteria. This gives innovators a faster route to market for therapies that address an unmet medical need, balanced against firm post-market confirmation obligations.

The table below summarizes how the old and new approaches compare.

The Terms and Conditions Process Step by Step

Health Canada follows a defined process built around an anticipatory letter, a chance to respond, and a final T&C letter. Understanding the sequence helps sponsors respond effectively and protect their timelines.

The process generally works as follows.

1. Anticipatory T&C letter. Health Canada notifies the sponsor of its intent to impose T&Cs. The letter explains the risks and uncertainties identified, the reasons for the proposed conditions, the expected outcomes, the timeframes, and the opportunity to be heard.
2. Sponsor response within 30 days. The MAH should respond in writing, generally within 30 calendar days, with a plan to fulfill the conditions. The response can describe study methodology and timelines, object to the proposed conditions, suggest less burdensome alternatives, or request a meeting. If a sponsor does not respond, Health Canada may finalize the T&Cs based on the information it has.
3. Final T&C letter within 30 days of the response. After reviewing the response, Health Canada issues a final T&C letter that specifies the affected DINs, the conditions to fulfill, the information to submit, and the deadlines.
4. Public posting. Health Canada posts statements about the imposed T&Cs and their timelines on its website, without disclosing confidential business information, and updates the record as conditions are fulfilled or amended.

Timing of the anticipatory letter is flexible. It can be issued during pre-market review when conditions must be reflected in product labelling, at the time the NOC and DIN are issued, shortly after authorization, or at any point post-authorization when new information emerges. Importantly, for most cases the issuance of the NOC does not depend on the review of the sponsor's response to the anticipatory letter, so a confirmatory study disagreement does not necessarily delay market entry.

Lifecycle Obligations: Progress Reporting and Confirmatory Studies

Once T&Cs are in place, the market authorization holder owns a set of ongoing obligations that must be tracked and reported. The central obligation is usually a confirmatory study, but Health Canada may also request progress reports on the status of required activities.

Although progress reports are not mandated by regulation, Health Canada may request them on a case-by-case basis. When requested, a progress report should summarize outstanding conditions, state the status of any trial, explain that status, and describe the actions taken. Health Canada uses a defined set of status definitions that sponsors should build into their tracking systems.

The fulfilled status is the goal. It is reached only when Health Canada reviews the confirmatory submission and issues a notice of compliance approving updated labelling that reflects the confirmed evidence. Until then, the obligation remains open and enforceable. Building a compliant quality management system that captures these statuses and deadlines is essential for any company holding drugs with T&Cs.

What Happens to Generics and Biosimilars?

Subsequent-entry drugs can inherit terms and conditions from their reference product. A generic or biosimilar that relies on a Canadian reference product (CRP) or Canadian reference biologic drug (CRBD) carrying T&Cs may be assigned the same or similar conditions.

In many cases, a subsequent-entry sponsor will not have to repeat a confirmatory trial already underway for the reference product. Instead, the product monograph and packaging may need to reflect the promising nature of the efficacy evidence. However, there are scenarios where a generic or biosimilar sponsor could be required to generate data. A clear example is where the reference product's MAH cancels its DIN before completing the confirmatory studies. In that case, the subsequent-entry sponsor may be asked to provide data verifying clinical benefit in order to keep its product on the market.

This creates a due diligence point that is easy to miss. Before relying on a reference product, generic and biosimilar developers should confirm whether that product carries T&Cs and understand the status of any confirmatory work. Our audit and gap assessment services help companies surface these dependencies before they become commercial risks.

Compliance and Enforcement: The Stakes

Terms and conditions are enforceable under section 21.7 of the Food and Drugs Act, and non-compliance can carry serious consequences. This is the feature that most clearly distinguishes the new framework from the policy-based NOC/c model.

A market authorization holder that fails to fulfill T&Cs, including failing to submit trials or studies by the stated deadlines, may be held criminally liable. Health Canada applies a risk-based approach when it acts on information generated by T&Cs, and regulatory actions can include a stop-sale order, mandatory label changes, an order to conduct additional studies, suspension of the notice of compliance, or cancellation of the DIN. Health Canada's broader compliance and enforcement policy, POL-0001, governs how these actions are applied.

For generics and biosimilars, the enforcement picture has an added layer. If the reference product's MAH fails to fulfill its T&Cs or withdraws its product, a subsequent-entry sponsor that wants to keep marketing may have to provide its own supporting evidence, and Health Canada will decide whether that evidence is sufficient.

Compliance Checklist: Preparing for April 1, 2027

Use this checklist to assess readiness for the terms and conditions framework.

• Map every Canadian DIN in your portfolio and flag any product that could attract T&Cs, including older authorizations.
• Identify pipeline submissions for serious or severely debilitating conditions that may use the promising evidence pathway.
• Assess eligibility for Advance Consideration of Promising Evidence (ACPE) status to shorten review targets.
• Build confirmatory study plans, including realistic timelines and SNDS-C filing strategies, into submission planning.
• Establish a tracking system that captures trial status using Health Canada's definitions: pending, ongoing, delayed, terminated, submitted, and fulfilled.
• Create a 30-day response procedure for anticipatory T&C letters, with clear internal ownership and decision rights.
• Document a process to report terminated trials with safety, efficacy, or quality concerns to Health Canada within 15 days.
• Review reference product dependencies for any generic or biosimilar that relies on a CRP or CRBD with T&Cs.
• Align pharmacovigilance and risk management plans with potential T&C obligations.
• Train regulatory, clinical, quality, and labelling teams on the new framework before it takes effect.

Common Mistakes to Avoid

The most common mistake is treating terms and conditions as a post-approval problem rather than a submission-stage strategy. Sponsors who wait until they receive an anticipatory letter to think about confirmatory studies lose negotiating leverage and time.

Other frequent errors include underestimating the 30-day response window, failing to track confirmatory study status in a defensible system, overlooking the 15-day reporting trigger for terminated trials, and assuming that a generic or biosimilar is insulated from a reference product's conditions. Companies also sometimes assume T&Cs only apply to new approvals, when in fact Health Canada can impose them on long-authorized products when new information emerges. Each of these gaps is avoidable with early planning and a sound quality system.

Frequently Asked Questions

What are Health Canada terms and conditions for drugs?

Terms and conditions are enforceable obligations Health Canada can place on a drug's DIN under section C.01.014.21 of the Food and Drug Regulations to manage risks or resolve significant uncertainties about the drug's benefits, risks, or quality. They can require additional studies, monitoring programs, or more frequent safety reporting.

When does the new terms and conditions framework take effect?

The Agile Licensing amendments to the Food and Drug Regulations come into force on April 1, 2027. Health Canada published the supporting draft guidance on December 12, 2025, and the consultation closed on February 10, 2026.

Does this replace the Notice of Compliance with Conditions (NOC/c) policy?

Yes. Promising drugs for serious conditions that were previously approved under the NOC/c policy will instead be authorized with terms and conditions under section C.08.003.2, supported by a new promising evidence of clinical efficacy pathway.

What happens if a company does not comply with terms and conditions?

Terms and conditions are enforceable under section 21.7 of the Food and Drugs Act. Non-compliance can lead to criminal liability and regulatory actions including stop-sale orders, label changes, suspension of the notice of compliance, or cancellation of the DIN.

Do terms and conditions apply to generics and biosimilars?

They can. A subsequent-entry drug that relies on a Canadian reference product or reference biologic drug carrying terms and conditions may inherit the same or similar conditions, and in some cases may need to generate its own confirmatory data.

What is ACPE status?

Advance Consideration of Promising Evidence is a status for human drug submissions that, when criteria are met, results in reduced screening and review targets. It is part of the new promising evidence pathway and is designed to speed access to therapies that address an unmet medical need.

How MFLRC Can Help

MF License and Regulatory Consultants (MFLRC) helps drug sponsors, market authorization holders, and manufacturers prepare for the terms and conditions framework with practical, defensible support across the regulatory lifecycle. Our work includes:

• Regulatory strategy and licensing support to position new drug submissions, including promising evidence and ACPE submissions, for the best possible review outcome.
• Gap assessments that map your portfolio against the new T&C authority and identify products at risk of post-market obligations.
• Quality management and SOP development so your systems can track confirmatory study status, deadlines, and reporting triggers with confidence.
• Audit and inspection-readiness services to verify that your T&C tracking and pharmacovigilance processes hold up under scrutiny.
• QAP and quality assurance support for organizations that need senior, hands-on regulatory expertise without adding permanent headcount.

With more than 20 years of experience across pharmaceuticals, biologics, natural health products, medical devices, and other regulated sectors, MFLRC translates complex Health Canada requirements into clear, actionable plans.

Conclusion

The terms and conditions framework is more than a renaming of NOC/c. It is a structural shift toward lifecycle regulation, backed by enforceable obligations and broad authority over almost any drug with a DIN. The replacement of the NOC/c policy with a regulated promising evidence pathway gives innovators a clearer, faster route to market for therapies that meet an unmet medical need, while raising the bar on post-market accountability.

With the amendments taking effect on April 1, 2027, sponsors have a finite window to align their submission strategies, confirmatory study planning, and quality systems. The companies that prepare now will move through the transition with confidence. Those that wait may find themselves negotiating obligations under pressure. Early, disciplined planning is the surest path to sustainable market access in Canada.

Sources and References

• Health Canada. Draft guidance on terms and conditions for human and veterinary drugs: Overview. December 12, 2025. canada.ca
• Health Canada. About terms and conditions. December 12, 2025. canada.ca
• Health Canada. Terms and conditions letters. December 12, 2025. canada.ca
• Health Canada. Progress reporting. December 12, 2025. canada.ca
• Health Canada. Compliance and enforcement. December 12, 2025. canada.ca
• Health Canada. Draft guidance on drug submissions based on promising evidence and terms and conditions. December 12, 2025. canada.ca
• Canada Gazette, Part 2, Volume 158, Number 26: Regulations Amending Certain Regulations Made Under the Food and Drugs Act (Agile Licensing), SOR/2024-238. December 18, 2024. gazette.gc.ca